Human flavin-containing monooxygenases
- PMID: 16402899
- DOI: 10.1146/annurev.pharmtox.46.120604.141043
Human flavin-containing monooxygenases
Abstract
This review summarizes recent information concerning the pharmacological and toxicological significance of the human flavin-containing monooxygenase (FMO, EC 1.14.13.8). The human FMO oxygenates nucleophilic heteroatom-containing chemicals and drugs and generally converts them into harmless, polar, readily excreted metabolites. Sometimes, however, FMO bioactivates chemicals into reactive materials that can cause toxicity. Most of the interindividual differences of FMO are due to genetic variability and allelic variation, and splicing variants may contribute to interindividual and interethnic variability observed for FMO-mediated metabolism. In contrast to cytochrome P450 (CYP), FMO is not easily induced nor readily inhibited, and potential adverse drug-drug interactions are minimized for drugs prominently metabolized by FMO. These properties may provide advantages in drug design and discovery, and by incorporating FMO detoxication pathways into drug candidates, more drug-like materials may be forthcoming. Although exhaustive examples are not available, physiological factors can influence FMO function, and this may have implications for the clinical significance of FMO and a role in human disease.
Similar articles
-
Some distinctions between flavin-containing and cytochrome P450 monooxygenases.Biochem Biophys Res Commun. 2005 Dec 9;338(1):599-604. doi: 10.1016/j.bbrc.2005.08.009. Epub 2005 Aug 11. Biochem Biophys Res Commun. 2005. PMID: 16112078 Review.
-
Role of flavin-containing monooxygenase in drug development.Expert Opin Drug Metab Toxicol. 2008 Dec;4(12):1507-21. doi: 10.1517/17425250802522188. Expert Opin Drug Metab Toxicol. 2008. PMID: 19040327 Review.
-
The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development.Drug Discov Today. 2004 Jul 1;9(13):574-81. doi: 10.1016/S1359-6446(04)03136-8. Drug Discov Today. 2004. PMID: 15203093 Review.
-
Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism.Pharmacol Ther. 2005 Jun;106(3):357-87. doi: 10.1016/j.pharmthera.2005.01.001. Pharmacol Ther. 2005. PMID: 15922018 Free PMC article. Review.
-
Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation.Drug Metab Dispos. 2002 Oct;30(10):1043-52. doi: 10.1124/dmd.30.10.1043. Drug Metab Dispos. 2002. PMID: 12228178 Review.
Cited by
-
Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development.Acta Pharm Sin B. 2022 Jun;12(6):2751-2777. doi: 10.1016/j.apsb.2022.03.009. Epub 2022 Mar 17. Acta Pharm Sin B. 2022. PMID: 35755285 Free PMC article. Review.
-
Indoles Derived From Glucobrassicin: Cancer Chemoprevention by Indole-3-Carbinol and 3,3'-Diindolylmethane.Front Nutr. 2021 Oct 1;8:734334. doi: 10.3389/fnut.2021.734334. eCollection 2021. Front Nutr. 2021. PMID: 34660663 Free PMC article. Review.
-
Comparative milk proteome analysis of Kashmiri and Jersey cattle identifies differential expression of key proteins involved in immune system regulation and milk quality.BMC Genomics. 2020 Feb 14;21(1):161. doi: 10.1186/s12864-020-6574-4. BMC Genomics. 2020. PMID: 32059637 Free PMC article.
-
Trichloroethylene biotransformation and its role in mutagenicity, carcinogenicity and target organ toxicity.Mutat Res Rev Mutat Res. 2014 Oct-Dec;762:22-36. doi: 10.1016/j.mrrev.2014.04.003. Mutat Res Rev Mutat Res. 2014. PMID: 25484616 Free PMC article. Review.
-
Synthetic Methodologies and Therapeutic Potential of Indole-3-Carbinol (I3C) and Its Derivatives.Pharmaceuticals (Basel). 2023 Feb 5;16(2):240. doi: 10.3390/ph16020240. Pharmaceuticals (Basel). 2023. PMID: 37259386 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
